195 related articles for article (PubMed ID: 18032792)
1. Therapy for polycystic kidney disease? It's water, stupid!
Grantham JJ
J Am Soc Nephrol; 2008 Jan; 19(1):1-7. PubMed ID: 18032792
[No Abstract] [Full Text] [Related]
2. Role of vasopressin antagonists.
Torres VE
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1212-8. PubMed ID: 18434616
[TBL] [Abstract][Full Text] [Related]
3. Polycystic kidney disease: hereditary and acquired.
Grantham JJ
Adv Intern Med; 1993; 38():409-20. PubMed ID: 8438648
[No Abstract] [Full Text] [Related]
4. Metabolic Changes in Polycystic Kidney Disease as a Potential Target for Systemic Treatment.
Haumann S; Müller RU; Liebau MC
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32847032
[TBL] [Abstract][Full Text] [Related]
5. Autosomal dominant polycystic kidney disease: pathophysiology and treatment.
Rapoport J
QJM; 2007 Jan; 100(1):1-9. PubMed ID: 17164322
[No Abstract] [Full Text] [Related]
6. [New therapeutic prospects in autosomal dominant polycystic kidney disease].
Torra R
Nefrologia; 2008; 28(3):257-62. PubMed ID: 18590491
[No Abstract] [Full Text] [Related]
7. Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease.
Meijer E; Boertien WE; Zietse R; Gansevoort RT
Kidney Blood Press Res; 2011; 34(4):235-44. PubMed ID: 21691126
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis, pathogenesis, and treatment prospects in cystic kidney disease.
Bergmann C; Frank V; Küpper F; Kamitz D; Hanten J; Berges P; Mager S; Moser M; Kirfel J; Büttner R; Senderek J; Zerres K
Mol Diagn Ther; 2006; 10(3):163-74. PubMed ID: 16771602
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases.
Torres VE; Harris PC
Nat Clin Pract Nephrol; 2006 Jan; 2(1):40-55; quiz 55. PubMed ID: 16932388
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel?
Walz G
Nephrol Dial Transplant; 2006 Jul; 21(7):1752-7. PubMed ID: 16705023
[No Abstract] [Full Text] [Related]
11. Vasopressin antagonists in polycystic kidney disease.
Torres VE
Semin Nephrol; 2008 May; 28(3):306-17. PubMed ID: 18519091
[TBL] [Abstract][Full Text] [Related]
12. Models of polycystic kidney disease.
Upadhya P
Methods Mol Med; 2003; 86():13-28. PubMed ID: 12886759
[No Abstract] [Full Text] [Related]
13. [Autosomal dominant polycystic kidney disease].
Horie S
Nihon Jinzo Gakkai Shi; 2011; 53(1):6-9. PubMed ID: 21370570
[No Abstract] [Full Text] [Related]
14. V2 receptor antagonists in cystic kidney diseases: an exciting step towards a practical treatment.
Bennett WM
J Am Soc Nephrol; 2005 Apr; 16(4):838-9. PubMed ID: 15728776
[No Abstract] [Full Text] [Related]
15. Autosomal recessive polycystic kidney disease: clinical features and genetics.
Zerres K; Rudnik-Schöneborn S; Mücher G
Adv Nephrol Necker Hosp; 1996; 25():147-57. PubMed ID: 8717625
[No Abstract] [Full Text] [Related]
16. A case for water in the treatment of polycystic kidney disease.
Torres VE; Bankir L; Grantham JJ
Clin J Am Soc Nephrol; 2009 Jun; 4(6):1140-50. PubMed ID: 19443627
[TBL] [Abstract][Full Text] [Related]
17. [Modern treatment of autosomal dominant polycystic kidney disease].
Wołyniec W; Jankowska MM; Rutkowski B
Pol Merkur Lekarski; 2008 Oct; 25(148):374-9. PubMed ID: 19145940
[TBL] [Abstract][Full Text] [Related]
18. Polycystic kidney disease: will it become treatable?
Gross P
Pol Arch Med Wewn; 2008 May; 118(5):298-301. PubMed ID: 18619180
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic interventions for autosomal dominant polycystic kidney disease.
Edelstein CL
Nephrol News Issues; 2008 Mar; 22(3):25-6. PubMed ID: 18372677
[TBL] [Abstract][Full Text] [Related]
20. Targeting cyst initiation in ADPKD.
Leuenroth SJ; Crews CM
J Am Soc Nephrol; 2009 Jan; 20(1):1-3. PubMed ID: 19118147
[No Abstract] [Full Text] [Related]
[Next] [New Search]
